ARTICLE | Company News
Orexigen, Kwang Dong deal
November 9, 2015 8:00 AM UTC
Orexigen granted Kwang Dong rights to develop and commercialize weight management drug Contrave naltrexone/bupropion in South Korea. Kwang will fund regulatory submissions and commercialization in the region. ...